Patients whose advanced non-small cell lung cancers harbor the RET gene fusion should receive initial treatment with the RET-targeted agent selpercatinib rather than chemotherapy or chemotherapy combined with immunotherapy.

This clear message comes from the randomized Phase III LIBRETTO-431 study reported at ESMO Congress 2023 by Herbert Ho Fung Loong, MBBS, FRCP, Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong in China.

After his talk in Madrid, OncTimesTalk correspondent Peter M. Goodwin talked with him about the study findings and clinical implications, as well as selpercatinib’s role in the landscape of cancer treatments along with other targeted therapies, chemotherapy, and immunotherapy.